Eisai Ltd., of Hatfield, U.K., said the EMA's Committee for Medicinal Products for Human Use issued a positive opinion for Kisplyx (lenvatinib) in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior VEGF-targeted therapy. The opinion was issued following the evaluation of results from a pivotal phase II trial, which show lenvatinib plus everolimus significantly extended progression-free survival in patients with unresectable advanced RCC vs. everolimus alone.